Share this article
Pharma Giant Tests IBM Blockchain in Bid to Improve Clinical Trials
Pharma giant Boehringer Ingelheim is set to trial IBM blockchain in Canada to raise the quality of processes and records in clinical trials.
Updated Dec 12, 2022, 12:42 p.m. Published Feb 13, 2019, 9:00 a.m.
Make us preferred on Google
A Germany-based pharmaceutical multinational's Canadian arm is set to trial IBM blockchain in Canada in a bid to raise the quality of clinical trials.
Boehringer Ingelheim (Canada) announced Tuesday that it has partnered with IBM “to improve trust, transparency, patient safety and patient empowerment in clinical trials” using the tech giant's blockchain platform.
STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
The firm said the trial aims to address quality issues with clinical trial processes and records, which are currently “often erroneous or incomplete” and could potentially put patient safety at risk.
The project will test how blockchain can help provide a decentralized framework that preserves the integrity of data, provides "provenance and transparency," and enables the automation of processes, ultimately boosting patient safety and reducing costs.
“The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment,” said Dr. Uli Brödl, vice president for medical and regulatory affairs at Boehringer Ingelheim (Canada).
IBM Canada’s general manager for services, Claude Guay, said:
“We’ve been using blockchain in other industries, and we are now investigating how we can use this technology to give Canadian patients the same level of security and trust when it comes to their personal health information.”
Other major pharmaceutical firms have also been exploring the potential benefits of integrating blockchain tech. In January 2018, Pfizer, Amgen and Sanofi were eyeing blockchain as a way of streamlining the process of developing and testing new drugs.
Last June, Merck was seeking a patent for a way to use blockchain in order to track goods as they move through the supply chain and tackle the issue of counterfeit meds. Indian government think tank NITI Aayog was also working on a blockchain solution aimed to combat the country’s roaring counterfeit drugs trade last April.
Test tubes in medical lab image via Shutterstock
More For You
KuCoin captured a record share of centralised exchange volume in 2025, with more than $1.25tn traded as its volumes grew faster than the wider crypto market.
What to know:
- KuCoin recorded over $1.25 trillion in total trading volume in 2025, equivalent to an average of roughly $114 billion per month, marking its strongest year on record.
- This performance translated into an all-time high share of centralised exchange volume, as KuCoin’s activity expanded faster than aggregate CEX volumes, which slowed during periods of lower market volatility.
- Spot and derivatives volumes were evenly split, each exceeding $500 billion for the year, signalling broad-based usage rather than reliance on a single product line.
- Altcoins accounted for the majority of trading activity, reinforcing KuCoin’s role as a primary liquidity venue beyond BTC and ETH at a time when majors saw more muted turnover.
- Even as overall crypto volumes softened mid-year, KuCoin maintained elevated baseline activity, indicating structurally higher user engagement rather than short-lived volume spikes.
More For You
XRP drops 4% as traders watch whether $1.88 support holds
Price stabilizes near recent lows after a volatile pullback from above $2.
What to know:
- XRP slipped nearly 4% as bitcoin fell below $88,000, with price action driven more by market structure and positioning than by changes to Ripple’s fundamentals.
- Spot XRP ETFs saw about $40.6 million in weekly outflows, suggesting institutional profit-taking and rotation rather than a loss of confidence in the asset.
- XRP remains range-bound in a tight consolidation between support around $1.88 and resistance near $1.93–$1.95, with fading volume pointing to a larger move once the current stalemate resolves.
Top Stories
